Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14653322 | 0.98 | USP2 (0.53) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL14114421 | 0.96 | USP2 (0.51) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL40106 | 0.96 | USP2 (0.51) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL21142638 | 0.95 | HPGD (0.58) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL22931754 | 0.95 | HPGD (0.50) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL19410300 | 0.95 | HPGD (0.50) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL21259476 | 0.94 | HPGD (0.57) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL7620463 | 0.93 | MEN1 (0.50) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL24059733 | 0.93 | HPGD (0.59) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Piperidine SCHEMBL7357986 | 0.93 | HPGD (0.59) | USP2SMN1; SMN2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025217552-A1 | 2-(TERT-BUTYL)-4-METHYLPHENYL APPENDED 1,4-DIAZEPANE BASED NOVEL TFEB ACTIVATING COMPOUNDS AS AUTOPHAGY MODULATORS FOR NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE (AD) | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-10-16 | — | — | WO | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-114230569-A | Thiohydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20150368181-A1 | RECYCLABLE CHIRAL CATALYST FOR ASYMMETRIC NITROALDOL REACTION AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-24 | — | — | US | disclosed |
| US-6897219-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2005-05-24 | — | — | US | disclosed |
| US-6825189-B1 | TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION | NEUROSEARCH A/S (DK) | 2004-11-30 | — | — | US | disclosed |
| EP-1027336-B1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH AS (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | NEUROSEARCH A/S | 2004-04-15 | — | — | US | disclosed |
| EP-1027336-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021834-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368181-A1 | RECYCLABLE CHIRAL CATALYST FOR ASYMMETRIC NITROALDOL REACTION AND PROCESS FOR THE PREPARATION THEREOF | ECH1, ALDH3A1, REN | USP2 3274/4885SMN1; SMN2 3847/4885HPGD 378/4885 |
| US-11560381-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | USP2 2269/4885SMN1; SMN2 368/4885HPGD 2919/4885 |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | OGFR, CBR3, OGFRL1 | USP2 4521/4885SMN1; SMN2 2319/4885HPGD 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.